Background
death, tumors
METASTATIC COLORECTAL CANCER, TUMORS, SOLID TUMORS
The cell surface receptor programmed cell death protein-1 (PD-1) plays an important role in down-regulating the immune system and suppressing T cell activity [Nofazinlimab (formerly CS1003) is a humanized, recombinant immunoglobulin G4 anti-PD-1 monoclonal antibody (mAb). Nofazinlimab is one of a few anti-PD-1 antibodies that can recognize both human and murine PD-1. The binding potency of nofazinlimab to human PD-1 was comparable to that of pembrolizumab (KRegorafenib is an oral multi-kinase inhibitor that has demonstrated modest activity and survival gains in metastatic colorectal cancer (mCRC) after progression on standard-of-care therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-vascular endothelial growth factor therapy, and, in the case of KRAS wildtype tumors, anti-epidermal growth factor receptor therapy [Here we report the findings of the first-in-human phase 1 study of nofazinlimab, in monotherapy in patients with solid tumors, and in combination with regorafenib in patients with mCRC (NCT03475251).